Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
PGE1 pharmacology in arterial occlusive disease may inform therapy; leaves open clinical efficacy pending controlled trials.
European Journal of Clinical InvestigationVolume 18, Issue 6 p. 549-554 Prostaglandin E1 and arterial occlusive disease: pharmacological considerations TH. SIMMET, Corresponding Author TH. SIMMET Institute of Pharmacology and Toxicology, Ruhr-University of Bochum, Im Lottental, D-4360 Bochum 1, FRG*To whom correspondence should be addressed.Search for more papers by this authorB. A. PESKAR, B. A. PESKAR Institute of Pharmacology and Toxicology, Ruhr-University of Bochum, Im Lottental, D-4360 Bochum 1, FRGSearch for more papers by this author TH. SIMMET, Corresponding Author TH. SIMMET Institute of Pharmacology and Toxicology, Ruhr-University of Bochum, Im Lottental, D-4360 Bochum 1, FRG*To whom correspondence should be addressed.Search for more papers by this authorB. A. PESKAR, B. A. PESKAR Institute of Pharmacology and Toxicology, Ruhr-University of Bochum, Im Lottental, D-4360 Bochum 1, FRGSearch for more papers by this author First published: December 1988 https://doi.org/10.1111/j.1365-2362.1988.tb01266.xCitations: 33AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.
No takes yet. Share an insight, caveat, or question.
Simmet et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: